What It Is

PT-141, also known as bremelanotide, is a synthetic peptide primarily researched for its effects on sexual function and libido in both men and women. Unlike traditional treatments for sexual dysfunction that act on the vascular system, PT-141 works directly on the central nervous system by targeting melanocortin receptors (particularly MC3 and MC4), which are involved in regulating sexual behavior and energy balance.

This central mechanism is what distinguishes PT-141 from PDE5 inhibitors, which primarily affect physical blood-flow response rather than desire itself — PT-141 is researched for its influence on sexual motivation and responsiveness.

Who May Benefit

• Low libido research, both sexes
• Sexual dysfunction research where vascular treatments haven’t addressed the underlying desire component
• General sexual-wellness research

What to Expect

Onset is generally discussed within 30–60 minutes of administration, taken 30 minutes to 1 hour before intended activity.

Facial flushing shortly after administration is commonly reported and is generally considered an expected sign it is taking effect rather than a concerning reaction. Nausea and transient anxious feelings are also commonly reported and generally resolve on their own.

What to Pair It With

Reconstitution

Suggested Research Dosing Strategy

Administration Notes

Intranasal administration. Facial flushing shortly after use is common and generally expected.

Nausea and transient anxious feelings have been reported and generally resolve without intervention.

Research Considerations

PT-141’s central mechanism (acting on melanocortin receptors in the brain rather than vascular tissue) is what allows it to influence desire and arousal directly, which is mechanistically distinct from vascular-acting treatments for sexual dysfunction.

It has been researched in both male and female sexual health contexts, making it one of the few compounds in this category studied across both sexes.